小细胞肺癌免疫治疗的研究进展

靳 晓妮1, 李 国元2
1、青海大学
2、青海大学附属医院肿瘤内科二病区

摘要


小细胞肺癌small cell lung cancerSCLC是一种高侵袭性神经内分泌肿瘤传统化疗后易快速复发患
者预后极差。近年来免疫检查点抑制剂immune checkpoint inhibitorsICIs联合化疗显著改善了广泛期小细胞肺
癌extensive-stage SCLCES-SCLC的一线治疗效果但生存获益仍有限。本文系统综述了SCLC免疫治疗的关
键进展包括ES-SCLC化学免疫治疗及后线治疗进展并简要概述了局限期小细胞肺癌limited-stage SCLCLSSCLC免疫治疗的现状最后分析了当前争议问题及未来方向以期为临床实践和研究提供参考。

关键词


小细胞肺癌；广泛期小细胞肺癌；局限期小细胞肺癌；免疫检查点抑制剂

全文:

PDF


参考


[1]MEGYESFALVI Z, GAY C M, POPPER H,

et al. Clinical insights into small cell lung cancer: Tumor

heterogeneity, diagnosis, therapy, and future directions [J].

CA Cancer J Clin, 2023, 73(6): 620-52.

[2]LIANG J, GUAN X, BAO G, et al. Molecular

subtyping of small cell lung cancer [J]. Semin Cancer Biol,

2022, 86(Pt 2): 450-62.

[3]DINGEMANS A-M, FRüH M, ARDIZZONI

A, et al. Small-cell lung cancer: ESMO Clinical Practice

Guidelines for diagnosis, treatment and follow-up ☆ [J].

Annals of Oncology, 2021, 32(7): 839-53.

[4]GUO H, LI L, CUI J. Advances and challenges in

immunotherapy of small cell lung cancer [J]. Chinese journal

of cancer research = Chung-kuo yen cheng yen chiu, 2020,

32(1): 115-28.

[5]HORN L, MANSFIELD A S, SZCZĘSNA A, et al.

First-Line Atezolizumab plus Chemotherapy in ExtensiveStage Small-Cell Lung Cancer [J]. The New England journal

of medicine, 2018, 379(23): 2220-9.

[6]PAZ-ARES L, DVORKIN M, CHEN Y, et al.

Durvalumab plus platinum-etoposide versus platinumetoposide in first-line treatment of extensive-stage small-cell

lung cancer (CASPIAN): a randomised, controlled, open-label,

phase 3 trial [J]. The Lancet, 2019, 394(10212): 1929-39.

[7]CHENG Y, SPIGEL D R, CHO B C, et al.

Durvalumab after chemoradiotherapy in limited-stage smallcell lung cancer [J]. New England Journal of Medicine, 2024,

391(14): 1313-27.

[8]CHENG Y, HAN L, WU L, et al. Serplulimab vs.

placebo combined with chemotherapy as first-line treatment

for extensive-stage small-cell lung cancer: Extended

follow-up results and patient-reported outcomes from the

international phase 3 ASTRUM-005 study [Z]. American

Society of Clinical Oncology. 2024

[9]CHENG Y, FAN Y, ZHAO Y, et al. Tislelizumab

plus platinum and etoposide versus placebo plus platinum and

etoposide as first-line treatment for extensive-stage SCLC

(RATIONALE-312): a multicenter, double-blind, placebocontrolled, randomized, phase 3 clinical trial [J]. Journal of

Thoracic Oncology, 2024, 19(7): 1073-85.

[10]CHENG Y, LIU Y, ZHANG W, et al. LBA93

EXTENTORCH: A randomized, phase III trial of toripalimab

versus placebo, in combination with chemotherapy as a firstline therapy for patients with extensive stage small cell lung

cancer (ES-SCLC) [J]. Annals of Oncology, 2023, 34: S1334.

[11]CHENG Y, CHEN J, ZHANG W, et al.

Benmelstobart, anlotinib and chemotherapy in extensivestage small-cell lung cancer: a randomized phase 3 trial [J].

Nat Med, 2024, 30(10): 2967-76.

[12]RECK M, DZIADZIUSZKO R, SUGAWARA

S, et al. Five-year survival in patients with extensive-stage

small cell lung cancer treated with atezolizumab in the Phase

III IMpower133 study and the Phase III IMbrella A extension

study [J]. Lung Cancer, 2024, 196: 107924.

[13]ELLIS P M, SWAMINATH A, POND G R.

Patterns of Relapse in Small Cell Lung Cancer: Competing

Risks of Thoracic versus CNS Relapse [J]. Curr Oncol, 2021,

28(4): 2778-88.

[14]RIELY G J, WOOD D E, ETTINGER D S, et

al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN

Clinical Practice Guidelines in Oncology [J]. J Natl Compr

Canc Netw, 2024, 22(4): 249-74.

[15]BLANCO A C, MENDIVIL A N, DE SPéVILLE

B D, et al. 1989MO Lurbinectedin (LUR) in combination

with pembrolizumab (PBL) in relapsed small cell lung

cancer (SCLC): the phase I/II LUPER study [J]. Annals of

Oncology, 2023, 34: S1060-S1.

[16]RUSSO-CABRERA J, AIX S P, COZAR P, et al.

1050P sensitization to immunotherapy through manipulation

of tumor transcription by lurbinectedin [J]. Annals of

Oncology, 2023, 34: S636.

[17]MOORE P A, ZHANG W, RAINEY G J, et al.

Application of dual affinity retargeting molecules to achieve

optimal redirected T-cell killing of B-cell lymphoma [J].Blood, 2011, 117(17): 4542-51.

[18]ZHOU S, LIU M, REN F, et al. The landscape of

bispecific T cell engager in cancer treatment [J]. Biomark Res,

2021, 9(1): 38.

[19]AHN M J, CHO B C, FELIP E, et al. Tarlatamab

for Patients with Previously Treated Small-Cell Lung Cancer

[J]. N Engl J Med, 2023, 389(22): 2063-75.

[20]CAPPELL K M, KOCHENDERFER J N. Longterm outcomes following CAR T cell therapy: what we know

so far [J]. Nat Rev Clin Oncol, 2023, 20(6): 359-71.

[21]TAKAHASHI N, HAO Z, VILLARUZ L C, et al.

Berzosertib Plus Topotecan vs Topotecan Alone in Patients

With Relapsed Small Cell Lung Cancer: A Randomized

Clinical Trial [J]. JAMA Oncol, 2023, 9(12): 1669-77.

[22]ROJO F, CORASSA M, MAVROUDIS D, et al.

International real-world study of DLL3 expression in patients

with small cell lung cancer [J]. Lung Cancer, 2020, 147: 237-43.

[23]ZHANG Y, TACHEVA-GRIGOROVA S K,

SUTTON J, et al. Allogeneic CAR T Cells Targeting DLL3

Are Efficacious and Safe in Preclinical Models of Small Cell

Lung Cancer [J]. Clin Cancer Res, 2023, 29(5): 971-85.

[24]JASPERS J E, KHAN J F, GODFREY W D, et

al. IL-18-secreting CAR T cells targeting DLL3 are highly

effective in small cell lung cancer models [J]. J Clin Invest,

2023, 133(9).

[25]BELLIS R Y, ADUSUMILLI P S, AMADORMOLINA A. DLL3-targeted CAR T-cell therapy in preclinical models for small cell lung cancer: safety, efficacy, and

challenges [J]. Transl Lung Cancer Res, 2024, 13(3): 694-8.

[ 2 6 ] S A N D S J , S C H O E N F E L D A ,

SCHWARZENBERGER P, et al. 702 Phase 1 study of

DLL3-directed chimeric antigen receptor T-cells in subjects

with extensive stage small cell lung cancer [Z]. BMJ Specialist

Journals. 2023

[27]BLACKHALL F, JAO K, GREILLIER L, et al.

Efficacy and Safety of Rovalpituzumab Tesirine Compared

With Topotecan as Second-Line Therapy in DLL3-High

SCLC: Results From the Phase 3 TAHOE Study [J]. Journal

of thoracic oncology: official publication of the International

Association for the Study of Lung Cancer, 2021, 16(9): 1547-58.

[28]https://ir.zailaboratory.com/zh-hans/newsreleases/news-release-details/baxiangdll3deadc-zl

[29]https://www.prnewswire.com/news-releases/

kelun-biotechs-trop2-adc-sacituzumab-tirumotecan-sactmt-approved-for-marketing-in-second-indication-bynmpa-for-egfrm-nsclc-302396917.html

[30]RUDIN C, AHN J, JOHNSON M, et al.

Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small

Cell Lung Cancer (ES-SCLC): Interim Analysis of Ideatelung01: OA04. 03 [J]. Journal of Thoracic Oncology, 2024,

19(10): S15-S6.

[31]WAQAR S N, MORGENSZTERN D. Treatment

advances in small cell lung cancer (SCLC) [J]. Pharmacology

& therapeutics, 2017, 180: 16-23.

[32]程颖.透过ADRIATIC研究看局限期小细胞肺癌

治疗模式研究进展[J].循证医学，2024，24（3）：129-32.


Refbacks

  • 当前没有refback。